DAWNRAYS PHARMA announced its interim results, with a profit attributable to the parent company owners of approximately 105 million yuan, a year-on-year decrease of 78.79%
DAWNRAYS PHARMA announced its mid-year results for 2025, with a profit attributable to the parent company of approximately 105 million yuan, a year-on-year decrease of 78.79%. Revenue was approximately 630 million yuan, a year-on-year increase of 9.2%; gross profit was approximately 314 million yuan, a year-on-year decrease of 7.1%. In terms of sales, the sales volume of the antihypertensive "An" series products decreased by 5.7%, and sales revenue fell by 22.1%. The sales volume of the antiviral drug Entecavir dispersible tablets increased by 14.0%, and sales revenue grew by 8.7%. The overall profit decline was mainly due to the new factory not achieving scaled production, policy impacts, and increased R&D expenses
According to the Zhitong Finance APP, DAWNRAYS PHARMA (02348) announced its interim results for 2025, with revenue of approximately 630 million yuan, a year-on-year increase of 9.2%; gross profit of approximately 314 million yuan, a year-on-year decrease of 7.1%; profit attributable to the parent company of approximately 105 million yuan, a year-on-year decrease of 78.79%; earnings per share of 0.06961 yuan, and an interim dividend of 0.015 HKD per share.
Among them: sales volume of the "An" series products for treating hypertension decreased by 5.7% compared to the same period last year, and sales revenue decreased by 22.1%, mainly due to price declines in some regions affected by the national centralized procurement policy; sales volume of the antiviral drug Entecavir dispersible tablets increased by 14.0% compared to the same period last year, and sales revenue increased by 8.7%; sales volume of the Fujian DAWNRAYS product series for treating hyperlipidemia increased by 19.5% compared to the same period last year, and sales revenue increased by 16.6%; sales volume of cephalosporin powder injection increased by 47.9% compared to the same period last year, and sales revenue increased by 55.7%; as the group's wholly-owned subsidiary Suzhou DAWNRAYS PHARMA Co., Ltd. (Suzhou DAWNRAYS) and the group's wholly-owned subsidiary Lanzhou DAWNRAYS PHARMA Co., Ltd. gradually commercialized production, sales volume of intermediates and raw materials increased by 244.8% compared to the same period in 2024, and sales revenue increased by 142.7%.
The announcement stated that the decline in profit during this period was mainly due to the lack of large-scale commercial production at Suzhou DAWNRAYS and Lanzhou DAWNRAYS, price declines in some provinces for centralized procurement varieties such as the "An" series affected by national policies, and increased R&D expenses
